[1] Hallgreen et al, Benefit Risk Wave 2 Case study report Warfarin, March 2013
[2] Hallgreen et al, Benefit-risk assessment in a post-market setting: A case study integrating real-life experience into benefit-risk methodology, Pharmacoepidemiology and Drug Safety, 23, pages 974–983, doi: 10.1002/pds.3676 (2014).
[3] Van den Ham et al. Individualised assessment of the benefit and harm of warfarin in patients with atrial fibrillation, STROKE (submitted)
